Prospective intraindividual comparison of 18F-PSMA-7Q and 18F-DCFPyL PET/CT in patients with newly diagnosed prostate cancer.

Fluorine 18 (18F)-2-(3-{1-Carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (DCFPyL) is an early 18F-labeled prostate-specific membrane antigen (PSMA) targeted PET tracer that has shown promise in the diagnostic workup of prostate cancer and was recently approved by the US Food and Drug Administration. 18F-PSMA-7Q is a novel 18F-labeled PSMA-ligand PET tracer designed and synthesized by our team. This study compared the tracer-specific positron emission tomography/computed tomography (PET/CT) characteristics of 18F-PSMA-7Q with those of 18F-DCFPyL in patients with newly diagnosed prostate cancer.

Ten patients received similar doses of 18F-DCFPyL and 18F-PSMA-7Q 48 h apart and were imaged 1 h after injection on the same PET/CT scanner. Normal-organ biodistribution and tumor uptake were quantified using maximum and mean standardized uptake values (SUVmax and SUVmean), and all lesions were assigned a molecular imaging PSMA (miPSMA) score based on Prostate Cancer Molecular Imaging Standardized Evaluation criteria.

Seventeen lesions were detected in the 10 patients by both 18F-DCFPyL and 18F-PSMA-7Q. No statistically significant difference was observed when comparing the SUVmax and SUVmean of 18F-DCFPyL and 18F-PSMA-7Q in the lesions and parotid gland. The κ value for the miPSMA scores of the lesions between the two tracers was 0.907, indicating excellent agreement.

18F-PSMA-7Q can be used in clinical research as reliably as 18F-DCFPyL. The limited urinary excretion of 18F-PSMA-7Q may represent a potential advantage over 18F-DCFPyL for detection of lesions in the pelvis, which need to be verified by further studies.

Nuclear medicine communications. 2022 May 10 [Epub]

Yachao Liu, Xiaojun Zhang, Jiajin Liu, Jinming Zhang, Baixuan Xu

Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing, China.

email news signup